

David Roth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7856599/publications.pdf>

Version: 2024-02-01

41
papers

1,661
citations

567281

15
h-index

315739

38
g-index

41
all docs

41
docs citations

41
times ranked

1853
citing authors

#	ARTICLE	IF	CITATIONS
1	Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. <i>Lancet</i> , 2015, 386, 1537-1545.	13.7	625
2	DE NOVO MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS IN HEPATITIS C VIRUS-INFECTED RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1995, 59, 1676-1682.	1.0	133
3	Effect of Kidney Transplantation on Outcomes among Patients with Hepatitis C. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1152-1160.	6.1	128
4	Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. <i>Journal of Hepatology</i> , 2015, 63, 763-765.	3.7	102
5	Detection of Hepatitis C Virus Infection among Cadaver Organ Donors: Evidence for Low Transmission of Disease. <i>Annals of Internal Medicine</i> , 1992, 117, 470-475.	3.9	87
6	An Epidemiologic Study of Early Renal Replacement Therapy after Orthotopic Liver Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 228-233.	6.1	73
7	Hepatitis C Virus Infection in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2238-2246.	6.1	72
8	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 585-594.	8.1	71
9	Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. <i>Transplant International</i> , 2017, 30, 865-873.	1.6	58
10	Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. <i>Transplant International</i> , 2016, 29, 216-226.	1.6	48
11	Transmission of hepatitis C virus by kidney transplantation: impact of perfusion techniques and course of viremia post transplant. <i>Pediatric Nephrology</i> , 1995, 9, S29-S34.	1.7	28
12	Kidney Transplantation in the Patient with Hepatitis C Virus Infection. <i>Contributions To Nephrology</i> , 2012, 176, 77-86.	1.1	27
13	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. <i>Hepatology Research</i> , 2017, 47, 1340-1345.	3.4	24
14	Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases. <i>F1000Research</i> , 2016, 5, 2893.	1.6	24
15	A cluster of donor-derived <i>Cryptococcus neoformans</i> infection affecting lung, liver, and kidney transplant recipients: Case report and review of literature. <i>Transplant Infectious Disease</i> , 2018, 20, e12836.	1.7	22
16	Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up. <i>Transplant Immunology</i> , 2017, 40, 42-50.	1.2	13
17	KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. <i>American Journal of Kidney Diseases</i> , 2020, 75, 665-683.	1.9	13
18	Clinical outcomes in HIV+/HCV+ coinfecting kidney transplant recipients in the pre- and post-direct acting antiviral therapy eras: 10-year single center experience. <i>Clinical Transplantation</i> , 2019, 33, e13532.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal. <i>Pediatric Nephrology</i> , 2023, 38, 145-159.	1.7	12
20	Transplantation of Kidneys from HCV-Positive Donors: How to Best Use a Scarce Resource. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3139-3141.	6.1	11
21	Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. <i>World Journal of Hepatology</i> , 2017, 9, 833.	2.0	11
22	Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy. <i>Transplant Immunology</i> , 2014, 30, 88-92.	1.2	10
23	Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population: The Dawn of a New Era. <i>Seminars in Dialysis</i> , 2016, 29, 5-6.	1.3	10
24	Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low-dose corticosteroids in primary kidney transplantation: 18-year results. <i>Clinical Transplantation</i> , 2020, 34, e14123.	1.6	8
25	Treating hepatitis C virus in dialysis patients: How, when, and why?. <i>Seminars in Dialysis</i> , 2019, 32, 152-158.	1.3	7
26	Treatment and management options for the hepatitis C virus infected kidney transplant candidate. <i>Hemodialysis International</i> , 2018, 22, S36-S44.	0.9	5
27	A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment. <i>Kidney Medicine</i> , 2019, 1, 200-206.	2.0	5
28	Early Development of Acute Myelogenous Leukemia Following Kidney Transplantation: Possible Role of Multiple Serum Cytokines. <i>Leukemia and Lymphoma</i> , 1995, 19, 173-180.	1.3	3
29	Medical Management of the Kidney Transplant Recipient. <i>Primary Care - Clinics in Office Practice</i> , 2014, 41, 895-906.	1.6	3
30	Kidney Transplantation From a Hepatitis C Virus-Infected Donor Into an Uninfected Recipient: Ready for Prime Time?. <i>Kidney International Reports</i> , 2020, 5, 386-388.	0.8	3
31	Graft Failure Due to Nonadherence among 150 Prospectively-Followed Kidney Transplant Recipients at 18 Years Post-transplant: Our Results and Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 1334.	2.4	3
32	Predictors of reduced tacrolimus dose and trough level through 36 months post-transplant among 578 adult primary kidney transplant recipients. <i>Clinical Transplantation</i> , 2014, 28, 470-478.	1.6	2
33	Treating hepatitis C viral infection in patients with chronic kidney disease: When and how. <i>Clinical Liver Disease</i> , 2017, 9, 55-59.	2.1	2
34	Should My Patient Accept a Kidney from a Hepatitis C Virus-Infected Donor?. <i>Kidney360</i> , 2020, 1, 127-129.	2.1	2
35	End-Stage Renal Disease and Treatment of Hepatitis C Virus Infection. <i>Current Hepatology Reports</i> , 2018, 17, 78-82.	0.9	1
36	Treatment of HCV-infected patients with advanced kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 6-8.	9.6	1

#	ARTICLE	IF	CITATIONS
37	Hepatitis C Virus Infection in ESKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1735-1737.	4.5	1
38	Introduction to hepatitis C virus infection in patients with kidney disease: A roadmap for nephrologists. Seminars in Dialysis, 2019, 32, 91-92.	1.3	1
39	Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab. CKJ: Clinical Kidney Journal, 2009, 2, 395-397.	2.9	0
40	Impact of grazoprevir and elbasvir in the treatment of hepatitis C virusâ€infectd patients with chronic kidney disease and endâ€stage renal disease. Clinical Liver Disease, 2016, 7, 112-115.	2.1	0
41	In Reply to â€Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guidelineâ€™. American Journal of Kidney Diseases, 2021, 77, 152-153.	1.9	0